Endogenous inhibitory mechanisms in asthma.

Much of the research in asthma has focused on the multiple proinflammatory mechanisms involved in this complex inflammatory disease (1). Much less attention has been paid to endogenous antiinflammatory mechanisms that may counteract or limit the inflammatory process in asthma. It is possible that these inhibitory mechanisms might be defective, resulting in increased or more prolonged inflammation. Such mechanisms, if deficient, might also be important in determining the severity of asthma, which differs markedly and inexplicably between patients. Little is understood about the factors that determine severity in chronic inflammatory diseases, such as asthma, but it is possible that endogenous inhibitory mechanisms may be of critical importance. There has been relatively little research into endogenous inhibitory mechanisms in asthma, but it is likely that understanding these processes may give a better understanding of disease severity. This may also lead to novel therapeutic approaches, such as drugs that increase the release of endogenous inhibitors or mimic their effects. Such therapeutic approaches are attractive since they may restore antiinflammatory mechanisms to normal and thus carry a lower risk of adverse effects in the long term.

[1]  A. Choi,et al.  rapid communication Carbon monoxide provides protection against hyperoxic lung injury , 2022 .

[2]  P. Barnes,et al.  Mechanisms of prostaglandin E2 release by intact cells expressing cyclooxygenase-2: evidence for a 'two-component' model. , 1999, The Journal of pharmacology and experimental therapeutics.

[3]  K. Chung,et al.  Inflammatory mediators of asthma: an update. , 1998, Pharmacological reviews.

[4]  P. Barnes,et al.  Inhibitory cytokines in asthma. , 1998, Molecular medicine today.

[5]  P. Barnes,et al.  Raised levels of exhaled carbon monoxide are associated with an increased expression of heme oxygenase-1 in airway macrophages in asthma: a new marker of oxidative stress , 1998, Thorax.

[6]  P. Barnes,et al.  Haplotype associated with low interleukin-10 production in patients with severe asthma , 1998, The Lancet.

[7]  N. Minamino,et al.  Production of Adrenomedullin in Macrophage Cell Line and Peritoneal Macrophage* , 1998, The Journal of Biological Chemistry.

[8]  P. Barnes,et al.  Allergen-induced early and late asthmatic responses are not affected by inhibition of endogenous nitric oxide. , 1998, American journal of respiratory and critical care medicine.

[9]  P. Barnes,et al.  Effect of endogenous nitric oxide inhibition on airway responsiveness to histamine and adenosine-5′-monophosphate in asthma , 1998, Thorax.

[10]  Susan D. Spencer,et al.  The Orphan Receptor CRF2-4 Is an Essential Subunit of the Interleukin 10 Receptor , 1998, The Journal of experimental medicine.

[11]  M. Wills-Karp,et al.  Interleukin‐12 as a target for modulation of the inflammatory response in asthma , 1998, Allergy.

[12]  M. Su,et al.  Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. , 1998, The Journal of clinical investigation.

[13]  L Adorini,et al.  The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. , 1998, Annual review of immunology.

[14]  K. Kohno,et al.  Interleukin 18, a cytokine which resembles IL-1 structurally and IL-12 functionally but exerts its effect independently of both. , 1998, Clinical immunology and immunopathology.

[15]  K. Chung,et al.  Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. , 1998, American journal of respiratory and critical care medicine.

[16]  J. Goldblatt,et al.  Mutation screening of interferon‐gamma (IFNγ) as a candidate gene for asthma , 1997 .

[17]  R. Pauwels,et al.  Role of IFN-gamma in the inhibition of the allergic airway inflammation caused by IL-12. , 1997, American journal of respiratory cell and molecular biology.

[18]  R. Kastelein,et al.  IGIF Does Not Drive Th1 Development but Synergizes with IL-12 for Interferon-γ Production and Activates IRAK and NFκB , 1997 .

[19]  H Sasaki,et al.  Increased carbon monoxide in exhaled air of asthmatic patients. , 1997, American journal of respiratory and critical care medicine.

[20]  L. Fabbri,et al.  Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. , 1997, The Journal of clinical investigation.

[21]  L. Poulter,et al.  Allergen-induced cytokine production in atopic disease and its relationship to disease severity. , 1997, American journal of respiratory cell and molecular biology.

[22]  D. Umetsu,et al.  Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. , 1997, Journal of immunology.

[23]  L. Aarden,et al.  Reduced production of IL-12 and IL-12-dependent IFN-gamma release in patients with allergic asthma. , 1997, Journal of immunology.

[24]  H. Savelkoul,et al.  T cells subsets and cytokines in allergic and non-allergic children. II. Analysis and IL-5 and IL-10 mRNA expression and protein production. , 1997, Cytokine.

[25]  M. Goldman,et al.  IL-10: a potential therapy for allergic inflammation? , 1997, Immunology today.

[26]  H. Okamura,et al.  Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  E. Gelfand,et al.  Rush immunotherapy results in allergen-specific alterations in lymphocyte function and interferon-gamma production in CD4+ T cells. , 1997, The Journal of allergy and clinical immunology.

[28]  P. Barnes,et al.  Dual action of nitric oxide on airway plasma leakage. , 1997, American journal of respiratory and critical care medicine.

[29]  R. Martin,et al.  Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy. , 1997, American journal of respiratory and critical care medicine.

[30]  K. Chung,et al.  Human airway smooth muscle cells express and release RANTES in response to T helper 1 cytokines: regulation by T helper 2 cytokines and corticosteroids. , 1997, Journal of immunology.

[31]  S. Durham,et al.  Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. , 1997, The Journal of allergy and clinical immunology.

[32]  M. Lazarus,et al.  An investigation of polymorphism in the interleukin-10 gene promoter. , 1997, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[33]  R. Robbins,et al.  Inhibition of inducible nitric oxide synthase expression by interleukin‐4 and interleukin‐13 in human lung epithelial cells , 1996, Immunology.

[34]  D. Holbert,et al.  Immunomodulatory effects of IL-12 on allergic lung inflammation depend on timing of doses. , 1996, Journal of immunology.

[35]  A. Sousa,et al.  Expression of interleukin-1 beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium. , 1996, American journal of respiratory and critical care medicine.

[36]  S. Szefler,et al.  A novel action of IL-13: induction of diminished monocyte glucocorticoid receptor-binding affinity. , 1996, Journal of immunology.

[37]  K. Chung,et al.  Interleukin 13 inhibits macrophage inflammatory protein-1 alpha production from human alveolar macrophages and monocytes. , 1996, American journal of respiratory cell and molecular biology.

[38]  D. Yates,et al.  Endogenous nitric oxide is decreased in asthmatic patients by an inhibitor of inducible nitric oxide synthase. , 1996, American journal of respiratory and critical care medicine.

[39]  S. Wenzel,et al.  Interleukin-10 regulation in normal subjects and patients with asthma. , 1996, The Journal of allergy and clinical immunology.

[40]  C. Bertrand,et al.  Mice lacking the IFN-gamma receptor have impaired ability to resolve a lung eosinophilic inflammatory response associated with a prolonged capacity of T cells to exhibit a Th2 cytokine profile. , 1996, Journal of immunology.

[41]  C. Serhan,et al.  Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. , 1996, Journal of immunology.

[42]  R. Pauwels,et al.  Interleukin-12 inhibits antigen-induced airway hyperresponsiveness in mice. , 1996, American journal of respiratory and critical care medicine.

[43]  P. Barnes,et al.  NO or no NO in asthma? , 1996, Thorax.

[44]  M. Singer,et al.  Interleukin‐10 inhibits cytokine generation from mast cells , 1996, European journal of immunology.

[45]  D. Willis,et al.  Heme oxygenase: A novel target for the modulation of inflammatory response , 1996, Nature Medicine.

[46]  P. Howarth,et al.  Neuropeptide-containing nerves in endobronchial biopsies from asthmatic and nonasthmatic subjects. , 1995, American journal of respiratory cell and molecular biology.

[47]  J. Siegfried,et al.  Expression of adrenomedullin in normal human lung and in pulmonary tumors. , 1995, Endocrinology.

[48]  G. Hunninghake,et al.  Regulation of interleukin-1 receptor antagonist by Th1 and Th2 cytokines. , 1995, The American journal of physiology.

[49]  K. Hirata,et al.  Adrenomedullin inhibits the secretion of cytokine-induced neutrophil chemoattractant, a member of the interleukin-8 family, from rat alveolar macrophages. , 1995, Biochemical and biophysical research communications.

[50]  P. Barnes,et al.  Nitric oxide and airway disease. , 1995, Annals of medicine.

[51]  T. Takishima,et al.  Potential role of interleukin-1 in allergen-induced late asthmatic reactions in guinea pigs: suppressive effect of interleukin-1 receptor antagonist on late asthmatic reaction. , 1995, The Journal of allergy and clinical immunology.

[52]  D. Leduc,et al.  Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice. , 1995, The Journal of clinical investigation.

[53]  Peng Wang,et al.  Interleukin (IL)-10 Inhibits Nuclear Factor B (NFB) Activation in Human Monocytes , 1995, The Journal of Biological Chemistry.

[54]  I. Pavord,et al.  Bronchoprotective role for endogenous prostaglandin E2 , 1995, The Lancet.

[55]  J. Drazen,et al.  Neuropeptide content of lungs from asthmatic and nonasthmatic patients. , 1995, American journal of respiratory and critical care medicine.

[56]  T. Lee Lipoxin A4: a novel anti-inflammatory molecule? , 1995, Thorax.

[57]  Richard J Martin,et al.  The effects of nebulized recombinant interferon-γ in asthmatic airways , 1995 .

[58]  S. Kudoh,et al.  Adrenomedullin, a newly discovered hypotensive peptide, is a potent bronchodilator. , 1994, Biochemical and biophysical research communications.

[59]  J. Vane,et al.  Induction of cyclo‐oxygenase‐2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone , 1994, British journal of pharmacology.

[60]  L. Reece,et al.  Interleukin-1 receptor antagonist protein inhibits the synthesis of IgE and proinflammatory cytokines by allergen-stimulated mononuclear cells. , 1994, American journal of respiratory cell and molecular biology.

[61]  K. Chung,et al.  Alveolar macrophage-induced suppression of peripheral blood mononuclear cell responsiveness is reversed by in vitro allergen exposure in bronchial asthma. , 1994, The European respiratory journal.

[62]  M. Jordana,et al.  Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils , 1994, The Journal of experimental medicine.

[63]  Ho As,et al.  Interleukin-10 and its receptor. , 1994 .

[64]  P. O'Byrne,et al.  Effect of inhaled PGE2 on exercise-induced bronchoconstriction in asthmatic subjects. , 1994, American journal of respiratory and critical care medicine.

[65]  I. Pavord,et al.  Effect of inhaled prostaglandin E2 on allergen-induced asthma. , 1993, The American review of respiratory disease.

[66]  T. Sullivan,et al.  Endogenous cortisol regulates immunoglobulin E-dependent late phase reactions. , 1992, The Journal of clinical investigation.

[67]  W. Arend Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. , 1991, The Journal of clinical investigation.

[68]  R. Schleimer,et al.  Potential regulation of inflammation in the lung by local metabolism of hydrocortisone. , 1991, American journal of respiratory cell and molecular biology.

[69]  S. Said Neuropeptides as modulators of injury and inflammation. , 1990, Life sciences.

[70]  S. Ollerenshaw,et al.  Absence of immunoreactive vasoactive intestinal polypeptide in tissue from the lungs of patients with asthma. , 1989, The New England journal of medicine.

[71]  H. Sasaki,et al.  Late asthmatic response to Ascaris antigen challenge in dogs treated with metyrapone. , 1987, The American review of respiratory disease.